FAM92B Activators

Forskolin and IBMX, by increasing levels of cAMP, activate PKA, which could phosphorylate FAM92B or alter its regulatory environment. Similarly, PMA and Ionomycin, by activating PKC and increasing intracellular calcium, respectively, could change the phosphorylation status or conformation of FAM92B, potentially modifying its activity. U0126 and LY294002, through their inhibition of MEK1/2 and PI3K, could influence the extracellular signal-regulated kinase and AKT pathways, respectively, resulting in an altered cellular context that may affect FAM92B's function.

Rapamycin, by inhibiting mTOR, could impact protein synthesis pathways that intersect with FAM92B's regulation or function. SB203580 and PD98059, targeting p38 MAPK and MEK, respectively, could affect the MAPK pathway, thus influencing FAM92B's activity. SP600125, by inhibiting JNK, has the potential to alter transcriptional activity that could be crucial for FAM92B's regulation. Y-27632, as a ROCK inhibitor, could modulate cytoskeletal organization, impacting cellular processes related to FAM92B. Thapsigargin, by disrupting calcium homeostasis, could activate calcium-dependent signaling pathways that modulate FAM92B's activity.